Conflicts of interest
Final Results from Study 181: Randomized Phase 3 Study of FOLFIRI +/- Panitumumab for the Treatment of 2 nd ‑line Metastatic Colorectal Cancer. A. Sobrero , 1 M. Peeters, 2 T. Price, 3 Y. Hotko, 4 A. Cervantes, 5 M. Ducreux, 6 T. André, 7 E. Chan, 8 F. Lordick 9 Y. Tian, 10 R. Sidhu 10
219 views • 14 slides